OncoMed Pharmaceuticals Company Profile (NASDAQ:OMED)

About OncoMed Pharmaceuticals (NASDAQ:OMED)

OncoMed Pharmaceuticals logoOncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. The Company's therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11). Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4) in the Notch signaling pathway. Tarextumab is a human monoclonal antibody that binds to both the Notch2 and Notch3 receptors.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:OMED
  • CUSIP: N/A
  • Web: www.oncomed.com
  • Market Cap: $141.87 million
  • Outstanding Shares: 37,630,000
Average Prices:
  • 50 Day Moving Avg: $4.53
  • 200 Day Moving Avg: $4.19
  • 52 Week Range: $2.91 - $10.89
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.26
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $24.55 million
  • Price / Sales: 5.78
  • Book Value: ($1.43) per share
  • Price / Book: -2.64
  • EBITDA: ($82,330,000.00)
  • Net Margins: -350.49%
  • Return on Assets: -49.95%
  • Current Ratio: 3.39%
  • Quick Ratio: 3.39%
  • Average Volume: 180,748 shs.
  • Beta: 2.76
  • Short Ratio: 7.41

Frequently Asked Questions for OncoMed Pharmaceuticals (NASDAQ:OMED)

What is OncoMed Pharmaceuticals' stock symbol?

OncoMed Pharmaceuticals trades on the NASDAQ under the ticker symbol "OMED."

How were OncoMed Pharmaceuticals' earnings last quarter?

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) announced its earnings results on Wednesday, August, 2nd. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.10. The firm earned $6.20 million during the quarter, compared to analyst estimates of $6.08 million. The company's revenue for the quarter was down 7.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.91) EPS. View OncoMed Pharmaceuticals' Earnings History.

When will OncoMed Pharmaceuticals make its next earnings announcement?

OncoMed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, October, 30th 2017. View Earnings Estimates for OncoMed Pharmaceuticals.

Where is OncoMed Pharmaceuticals' stock going? Where will OncoMed Pharmaceuticals' stock price be in 2017?

8 brokerages have issued twelve-month price targets for OncoMed Pharmaceuticals' stock. Their forecasts range from $4.00 to $10.00. On average, they anticipate OncoMed Pharmaceuticals' share price to reach $6.00 in the next year. View Analyst Ratings for OncoMed Pharmaceuticals.

What are analysts saying about OncoMed Pharmaceuticals stock?

Here are some recent quotes from research analysts about OncoMed Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "OncoMed Pharmaceuticals, Inc. is a biopharmaceutical company which focuses on the discovering and developing monoclonal antibody therapeutics for cancer stem cells. It utilizes its technologies to identify, isolate and evaluate CSCs, validate multiple potential targets and pathways critical to CSC self-renewal and differentiation and develop antibody and other protein-based therapeutics. The company serves the healthcare industry and cancer therapy patients. OncoMed Pharmaceuticals, Inc. is based in Redwood City, United States. " (10/11/2017)
  • 2. Cantor Fitzgerald analysts commented, "Restructuring plan should lengthen cash runway by at least a year, and we view a focus on assets with potential milestone opportunities as a positive given." (4/25/2017)

Who are some of OncoMed Pharmaceuticals' key competitors?

Who are OncoMed Pharmaceuticals' key executives?

OncoMed Pharmaceuticals' management team includes the folowing people:

  • Paul J. Hastings, Chairman of the Board, Chief Executive Officer
  • Sunil Patel, Chief Financial Officer, Executive Vice President, Corporate Development and Finance and President
  • John A. Lewicki Ph.D., Executive Vice President - Research and Development
  • Austin Gurney Ph.D., Senior Vice President, Molecular and Cellular Biology
  • Tim Hoey Ph.D., Senior Vice President, Cancer Biology
  • Alicia J Hager J.D. Ph.D., Vice President, General Counsel
  • Jack W. Lasersohn J.D., Lead Independent Director
  • Perry A. Karsen, Director
  • Rick E. Winningham, Director
  • Elisha P. Gould III, Independent Director

How do I buy OncoMed Pharmaceuticals stock?

Shares of OncoMed Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OncoMed Pharmaceuticals' stock price today?

One share of OncoMed Pharmaceuticals stock can currently be purchased for approximately $3.77.

MarketBeat Community Rating for OncoMed Pharmaceuticals (NASDAQ OMED)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  176 (Vote Outperform)
Underperform Votes:  148 (Vote Underperform)
Total Votes:  324
MarketBeat's community ratings are surveys of what our community members think about OncoMed Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for OncoMed Pharmaceuticals (NASDAQ:OMED) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $6.00 (59.15% upside)
Consensus Price Target History for OncoMed Pharmaceuticals (NASDAQ:OMED)
Price Target History for OncoMed Pharmaceuticals (NASDAQ:OMED)
Analysts' Ratings History for OncoMed Pharmaceuticals (NASDAQ:OMED)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/6/2017SunTrust Banks, Inc.Reiterated RatingHold$4.00N/AView Rating Details
9/28/2017Jefferies Group LLCReiterated RatingBuy$5.00LowView Rating Details
9/19/2017Cantor FitzgeraldReiterated RatingHold$6.00LowView Rating Details
7/10/2017Piper Jaffray CompaniesSet Price TargetHold$5.00MediumView Rating Details
5/15/2017HC WainwrightLower Price TargetBuy -> Buy$9.00 -> $6.00LowView Rating Details
4/17/2017JMP SecuritiesDowngradeOutperform -> Market PerformLowView Rating Details
4/11/2017Leerink SwannBoost Price TargetMarket Perform$6.00 -> $10.00HighView Rating Details
4/11/2017BMO Capital MarketsDowngradeOutperform -> Market Perform$6.00HighView Rating Details
6/1/2016MizuhoLower Price TargetNeutral$45.00 -> $40.00N/AView Rating Details
12/3/2015Wells Fargo & CompanyInitiated CoverageOutperformN/AView Rating Details
(Data available from 10/19/2015 forward)


Earnings History for OncoMed Pharmaceuticals (NASDAQ:OMED)
Earnings by Quarter for OncoMed Pharmaceuticals (NASDAQ:OMED)
Earnings History by Quarter for OncoMed Pharmaceuticals (NASDAQ OMED)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/30/2017($0.41)N/AView Earnings Details
8/2/2017Q2 2017($0.50)($0.40)$6.08 million$6.20 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.62)($0.61)$5.85 million$6.20 millionViewListenView Earnings Details
3/8/2017Q4 2016($0.68)($0.60)$6.57 million$6.22 millionViewListenView Earnings Details
11/1/2016Q3($0.77)($0.77)$9.48 million$5.92 millionViewN/AView Earnings Details
8/9/2016Q216($0.81)($0.91)$8.09 million$6.67 millionViewN/AView Earnings Details
5/5/2016Q1($0.73)($0.90)$8.28 million$6.40 millionViewN/AView Earnings Details
3/10/2016Q4$0.41$1.50$44.55 million$6.80 millionViewListenView Earnings Details
11/5/2015Q315($0.80)($0.81)$5.84 million$4.70 millionViewListenView Earnings Details
8/10/2015Q215($0.49)($0.72)$13.78 million$4.70 millionViewListenView Earnings Details
5/7/2015Q115($0.35)($0.49)$15.35 million$9.70 millionViewN/AView Earnings Details
3/12/2015Q414($0.27)($0.50)$11.92 million$8.51 millionViewN/AView Earnings Details
11/4/2014($0.30)($0.18)$17.84 million$19.02 millionViewN/AView Earnings Details
8/7/2014Q214($0.03)($0.53)$21.28 million$6.00 millionViewN/AView Earnings Details
5/8/2014Q114($0.13)($0.47)$18.08 million$6.02 millionViewN/AView Earnings Details
3/18/2014Q4 13$0.15($0.15)$20.37 million$19.00 millionViewN/AView Earnings Details
11/12/2013Q3$0.12($0.15)ViewN/AView Earnings Details
9/3/2013Q2 2013($0.02)($0.83)$8.31 million$2.90 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for OncoMed Pharmaceuticals (NASDAQ:OMED)
2017 EPS Consensus Estimate: ($1.96)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.76)($0.63)($0.68)
Q2 20173($0.65)($0.37)($0.47)
Q3 20173($0.56)($0.32)($0.42)
Q4 20173($0.49)($0.32)($0.39)
(Data provided by Zacks Investment Research)


Dividend History for OncoMed Pharmaceuticals (NASDAQ:OMED)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for OncoMed Pharmaceuticals (NASDAQ:OMED)
Insider Ownership Percentage: 32.80%
Institutional Ownership Percentage: 51.72%
Insider Trades by Quarter for OncoMed Pharmaceuticals (NASDAQ:OMED)
Institutional Ownership by Quarter for OncoMed Pharmaceuticals (NASDAQ:OMED)
Insider Trades by Quarter for OncoMed Pharmaceuticals (NASDAQ:OMED)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/10/2017Alicia J HagerSVPSell1,248$4.24$5,291.52View SEC Filing  
10/10/2017Paul J HastingsCEOSell1,398$4.24$5,927.52View SEC Filing  
6/5/2017Perry A KarsenDirectorBuy10,000$3.46$34,600.00View SEC Filing  
5/26/2017Jonathan D RootDirectorSell13,880$3.71$51,494.80View SEC Filing  
5/25/2017Jack W LasersohnDirectorBuy34,614$3.37$116,649.18View SEC Filing  
5/23/2017Jack W LasersohnDirectorBuy20,000$3.55$71,000.00View SEC Filing  
5/19/2017Jonathan D RootDirectorSell7,487$3.70$27,701.90View SEC Filing  
5/16/2017Jack W LasersohnDirectorBuy23,507$3.49$82,039.43View SEC Filing  
4/4/2017Alicia J. HagerSVPSell4,316$9.06$39,102.96View SEC Filing  
4/4/2017Paul J. HastingsCEOSell6,473$9.06$58,645.38View SEC Filing  
4/4/2017Sunil PatelInsiderSell5,754$9.06$52,131.24View SEC Filing  
1/6/2017Paul J. HastingsCEOSell42,738$8.34$356,434.92View SEC Filing  
1/3/2017John A. LewickiEVPSell9,175$7.63$70,005.25View SEC Filing  
1/3/2017Timothy HoeySVPSell12,763$7.64$97,509.32View SEC Filing  
1/11/2016Jakob DupontSVPSell2,500$20.01$50,025.00View SEC Filing  
1/7/2016Alicia J. HagerVPSell1,623$22.28$36,160.44View SEC Filing  
1/7/2016John A. LewickiEVPSell2,162$22.28$48,169.36View SEC Filing  
1/6/2016Paul J. HastingsCEOSell2,412$22.28$53,739.36View SEC Filing  
11/27/2015Alicia J. HagerVPSell1,800$23.14$41,652.00View SEC Filing  
10/27/2015Alicia J. HagerVPSell5,400$21.00$113,400.00View SEC Filing  
10/26/2015Austin GurneyInsiderSell14,000$20.00$280,000.00View SEC Filing  
10/26/2015Jakob DupontSVPSell5,000$20.00$100,000.00View SEC Filing  
9/30/2015Jack W. LasersohnDirectorBuy11,210$16.01$179,472.10View SEC Filing  
9/29/2015Jack W. LasersohnDirectorBuy3,140$14.15$44,431.00View SEC Filing  
9/28/2015Jack W. LasersohnDirectorBuy10,000$14.74$147,400.00View SEC Filing  
7/10/2015Jakob DupontSVPSell2,500$20.13$50,325.00View SEC Filing  
7/6/2015Jakob DupontSVPSell2,500$21.22$53,050.00View SEC Filing  
6/29/2015Alicia J HagerVPSell1,800$22.67$40,806.00View SEC Filing  
6/22/2015Timothy HoeySVPSell5,000$26.07$130,350.00View SEC Filing  
6/16/2015John A LewickiEVPSell17,000$25.07$426,190.00View SEC Filing  
6/15/2015John A LewickiEVPSell8,500$24.92$211,820.00View SEC Filing  
5/27/2015Alicia J HagerVPSell1,800$23.07$41,526.00View SEC Filing  
5/18/2015Austin GurneyInsiderSell4,000$22.48$89,920.00View SEC Filing  
4/27/2015Alicia J HagerVPSell1,800$25.65$46,170.00View SEC Filing  
4/27/2015Timothy HoeySVPSell6,887$25.65$176,651.55View SEC Filing  
4/17/2015Austin GurneyInsiderSell4,000$25.51$102,040.00View SEC Filing  
4/10/2015Jakob DupontSVPSell1,500$26.51$39,765.00View SEC Filing  
4/2/2015John A LewickiEVPSell17,000$25.28$429,760.00View SEC Filing  
3/20/2015Sunil PatelInsiderSell18,000$27.76$499,680.00View SEC Filing  
3/17/2015Austin GurneyInsiderSell4,000$27.37$109,480.00View SEC Filing  
2/5/2015Timothy HoeySVPSell7,500$22.83$171,225.00View SEC Filing  
2/2/2015John A LewickiEVPSell4,000$22.49$89,960.00View SEC Filing  
1/20/2015Austin GurneyInsiderSell4,000$22.87$91,480.00View SEC Filing  
1/12/2015Jakob DupontSVPSell1,500$25.89$38,835.00View SEC Filing  
1/5/2015Jakob DupontSVPSell7,500$23.00$172,500.00View SEC Filing  
1/2/2015John A LewickiEVPSell4,000$22.10$88,400.00View SEC Filing  
12/31/2014Denise Pollard-KnightDirectorSell3,799$21.66$82,286.34View SEC Filing  
12/30/2014Denise Pollard-KnightDirectorSell17,607$21.63$380,839.41View SEC Filing  
12/18/2014Jonathan D RootDirectorSell13,052$21.05$274,744.60View SEC Filing  
12/17/2014Austin GurneyInsiderSell4,000$20.00$80,000.00View SEC Filing  
12/10/2014Denise Pollard-KnightDirectorSell32,940$21.78$717,433.20View SEC Filing  
12/9/2014Denise Pollard-KnightDirectorSell23,273$21.78$506,885.94View SEC Filing  
12/8/2014Denise Pollard-KnightDirectorSell1,727$21.68$37,441.36View SEC Filing  
12/5/2014Denise Pollard-KnightDirectorSell25,000$21.60$540,000.00View SEC Filing  
12/1/2014John A LewickiEVPSell4,000$21.19$84,760.00View SEC Filing  
11/5/2014Timothy HoeySVPSell2,500$19.51$48,775.00View SEC Filing  
10/29/2014Paul J HastingsCEOSell16,769$21.99$368,750.31View SEC Filing  
10/2/2014Austin GurneyInsiderSell4,000$20.00$80,000.00View SEC Filing  
10/2/2014John A LewickiEVPSell5,809$20.00$116,180.00View SEC Filing  
9/4/2014Jack W LasersohnDirectorBuy3,170$18.35$58,169.50View SEC Filing  
9/3/2014Jack W LasersohnDirectorBuy3,000$18.40$55,200.00View SEC Filing  
9/2/2014John A LewickiEVPSell2,191$20.01$43,841.91View SEC Filing  
8/22/2014Austin GurneyInsiderSell4,000$20.00$80,000.00View SEC Filing  
8/21/2014Deepika PakianathanDirectorBuy80,203$18.98$1,522,252.94View SEC Filing  
8/15/2014Jack W LasersohnDirectorBuy1,045$17.00$17,765.00View SEC Filing  
8/5/2014Timothy HoeySVPSell2,500$21.66$54,150.00View SEC Filing  
8/1/2014John A LewickiEVPSell4,000$20.98$83,920.00View SEC Filing  
7/29/2014Paul J HastingsCEOSell16,770$22.11$370,784.70View SEC Filing  
7/23/2014Jakob DupontSVPSell1,500$23.00$34,500.00View SEC Filing  
7/17/2014Austin GurneyInsiderSell4,000$20.46$81,840.00View SEC Filing  
7/1/2014John A LewickiEVPSell4,000$23.86$95,440.00View SEC Filing  
6/30/2014Denise Pollard-KnightDirectorSell11,485$23.59$270,931.15View SEC Filing  
6/26/2014Jakob DupontSVPSell1,500$23.00$34,500.00View SEC Filing  
6/25/2014Denise Pollard-KnightDirectorSell3,252$23.56$76,617.12View SEC Filing  
6/24/2014Denise Pollard-KnightDirectorSell64,561$24.08$1,554,628.88View SEC Filing  
6/17/2014Austin GurneyInsiderSell4,000$24.99$99,960.00View SEC Filing  
6/16/2014John A LewickiEVPSell4,000$24.59$98,360.00View SEC Filing  
6/10/2014Presidio Management Group ViiiMajor ShareholderSell13,052$24.57$320,687.64View SEC Filing  
5/12/2014Presidio Management Group Viiimajor shareholderSell46,327$21.99$1,018,730.73View SEC Filing  
7/23/2013Denise Pollard-KnightDirectorBuy58,824$17.00$1,000,008.00View SEC Filing  
7/23/2013Presidio Management Group ViiiMajor ShareholderBuy158,823$17.00$2,699,991.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for OncoMed Pharmaceuticals (NASDAQ:OMED)
Latest Headlines for OncoMed Pharmaceuticals (NASDAQ:OMED)
americanbankingnews.com logoOncoMed Pharmaceuticals, Inc. (OMED) Downgraded by Zacks Investment Research
www.americanbankingnews.com - October 15 at 11:32 PM
americanbankingnews.com logo$6.25 Million in Sales Expected for OncoMed Pharmaceuticals, Inc. (OMED) This Quarter
www.americanbankingnews.com - October 11 at 5:20 AM
americanbankingnews.com logo Brokerages Expect OncoMed Pharmaceuticals, Inc. (OMED) to Announce -$0.39 Earnings Per Share
www.americanbankingnews.com - October 9 at 10:24 PM
americanbankingnews.com logoOncoMed Pharmaceuticals, Inc. (OMED) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - October 8 at 10:36 PM
americanbankingnews.com logoOncoMed Pharmaceuticals' (OMED) Hold Rating Reiterated at SunTrust Banks, Inc.
www.americanbankingnews.com - October 7 at 12:00 PM
finance.yahoo.com logoWhat You Must Know About OncoMed Pharmaceuticals Inc’s (OMED) Risks
finance.yahoo.com - October 2 at 8:16 PM
americanbankingnews.com logoOncomed Pharmaceuticals Inc (OMED) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - October 1 at 6:42 AM
americanbankingnews.com logoJefferies Group LLC Reiterates Buy Rating for OncoMed Pharmaceuticals, Inc. (OMED)
www.americanbankingnews.com - September 28 at 8:00 AM
americanbankingnews.com logo-$0.39 Earnings Per Share Expected for OncoMed Pharmaceuticals, Inc. (OMED) This Quarter
www.americanbankingnews.com - September 21 at 8:52 AM
reuters.com logoBRIEF-OncoMed CEO Paul Hastings to take medical leave of absence
www.reuters.com - September 20 at 7:17 AM
bizjournals.com logoAs company fortunes shift, hard-charging Peninsula CEO takes medical leave
www.bizjournals.com - September 20 at 7:17 AM
americanbankingnews.com logoOncoMed Pharmaceuticals, Inc. (OMED) Receives Hold Rating from Cantor Fitzgerald
www.americanbankingnews.com - September 19 at 11:24 AM
feeds.benzinga.com logoOncoMed Chairman and CEO, Paul Hastings, to Take Medical Leave of Absence
feeds.benzinga.com - September 19 at 8:48 AM
globenewswire.com logoOncoMed Doses First Patient with GITRL-Fc in Phase 1a Clinical Trial - GlobeNewswire (press release)
globenewswire.com - September 14 at 8:47 AM
finance.yahoo.com logoOncoMed Doses First Patient with GITRL-Fc in Phase 1a Clinical Trial
finance.yahoo.com - September 14 at 8:47 AM
americanbankingnews.com logoOncoMed Pharmaceuticals, Inc. (OMED) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - September 6 at 6:40 AM
americanbankingnews.com logo Analysts Anticipate OncoMed Pharmaceuticals, Inc. (OMED) Will Announce Earnings of -$0.39 Per Share
www.americanbankingnews.com - September 2 at 4:10 PM
finance.yahoo.com logoETFs with exposure to OncoMed Pharmaceuticals, Inc. : August 31, 2017
finance.yahoo.com - September 1 at 6:47 AM
americanbankingnews.com logoReviewing OncoMed Pharmaceuticals (OMED) and Aptose Biosciences (APTO)
www.americanbankingnews.com - August 31 at 2:26 AM
americanbankingnews.com logoOncoMed Pharmaceuticals, Inc. (OMED) Given a $5.00 Price Target at Jefferies Group LLC
www.americanbankingnews.com - August 26 at 8:16 AM
finance.yahoo.com logoOncoMed Pharmaceuticals, Inc. :OMED-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
finance.yahoo.com - August 26 at 7:59 AM
americanbankingnews.com logo Analysts Anticipate OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) to Announce -$0.38 EPS
www.americanbankingnews.com - August 15 at 6:32 AM
americanbankingnews.com logoOncoMed Pharmaceuticals, Inc. (OMED) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 12 at 6:30 AM
americanbankingnews.com logoFY2017 EPS Estimates for OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Lifted by Cantor Fitzgerald
www.americanbankingnews.com - August 10 at 10:42 AM
americanbankingnews.com logoLeerink Swann Comments on OncoMed Pharmaceuticals, Inc.'s Q3 2017 Earnings (OMED)
www.americanbankingnews.com - August 7 at 7:34 AM
americanbankingnews.com logoSunTrust Banks Research Analysts Cut Earnings Estimates for OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED)
www.americanbankingnews.com - August 7 at 7:06 AM
americanbankingnews.com logoFY2017 Earnings Estimate for OncoMed Pharmaceuticals, Inc. (OMED) Issued By Jefferies Group
www.americanbankingnews.com - August 7 at 7:06 AM
finanznachrichten.de logoGainers & Losers Of Aug.3: OMED, OSUR, PACB, AGRX, ELGX...
www.finanznachrichten.de - August 4 at 6:41 AM
cnbc.com logoOncoMed reports 2Q loss
www.cnbc.com - August 4 at 6:41 AM
finance.yahoo.com logoETFs with exposure to OncoMed Pharmaceuticals, Inc. : August 4, 2017
finance.yahoo.com - August 4 at 6:41 AM
globenewswire.com logoOncoMed Announces Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 3 at 6:36 AM
seekingalpha.com logoOncoMed Pharmaceuticals' (OMED) CEO Paul Hastings on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 3 at 6:36 AM
finance.yahoo.com logoOncoMed Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 3 at 6:36 AM
finance.yahoo.com logoEdited Transcript of OMED earnings conference call or presentation 2-Aug-17 8:30pm GMT
finance.yahoo.com - August 3 at 6:36 AM
americanbankingnews.com logoOncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Expected to Post Quarterly Sales of $6.25 Million
www.americanbankingnews.com - July 29 at 7:08 AM
americanbankingnews.com logo Brokerages Expect OncoMed Pharmaceuticals, Inc. (OMED) to Post -$0.48 Earnings Per Share
www.americanbankingnews.com - July 28 at 12:26 AM
americanbankingnews.com logoAlkermes PLC (ALKS) versus OncoMed Pharmaceuticals (OMED) Head to Head Comparison
www.americanbankingnews.com - July 27 at 9:40 AM
nasdaq.com logoOncoMed Pharmaceuticals to Report Second Quarter Financial Results on August 2nd, 2017 - Nasdaq
www.nasdaq.com - July 27 at 6:05 AM
finance.yahoo.com logoOncoMed Pharmaceuticals to Report Second Quarter Financial Results on August 2nd, 2017
finance.yahoo.com - July 27 at 6:05 AM
americanbankingnews.com logoFinancial Contrast: Oncomed Pharmaceuticals (NASDAQ:OMED) vs. CytRx Corporation (CYTR)
www.americanbankingnews.com - July 18 at 4:57 PM
americanbankingnews.com logoOncomed Pharmaceuticals Inc (OMED) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - July 18 at 10:04 AM
americanbankingnews.com logoOncoMed Pharmaceuticals, Inc. (OMED) Short Interest Down 40.4% in June
www.americanbankingnews.com - July 17 at 7:24 AM
finance.yahoo.com logoETFs with exposure to OncoMed Pharmaceuticals, Inc. : July 12, 2017
finance.yahoo.com - July 13 at 7:38 AM
reuters.com logoBRIEF-Oncomed says GSK terminates license agreement with company
www.reuters.com - July 11 at 6:21 AM
americanbankingnews.com logoOncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - July 9 at 7:18 AM
americanbankingnews.com logoOncoMed Pharmaceuticals, Inc. (OMED) Expected to Post Quarterly Sales of $6.23 Million
www.americanbankingnews.com - July 5 at 11:46 AM
americanbankingnews.com logo Analysts Expect OncoMed Pharmaceuticals, Inc. (OMED) to Post -$0.47 EPS
www.americanbankingnews.com - July 3 at 8:26 PM
globenewswire.com logoGlobal Double Barreled Antibodies Drug Sales (BLINCYTO & Removab) & Pipeline Analysis 2017-2022
globenewswire.com - June 1 at 8:48 AM
seekingalpha.com logoIs OncoMed A Contrarian Buy?
seekingalpha.com - May 26 at 5:31 AM
businesswire.com logoNewman Ferrara LLP Announces Corporate Governance Investigation of OncoMed Pharmaceuticals Inc. - Business Wire (press release)
www.businesswire.com - May 16 at 10:04 AM



OncoMed Pharmaceuticals (OMED) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.